NasdaqGS:TYRABiotechs
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In?
Recent Phase II results for Dabogratinib, Tyra Biosciences (TYRA) experimental therapy for non-muscle invasive bladder cancer, have drawn fresh attention to the company, its late stage pipeline, and how the stock reflects that potential.
See our latest analysis for Tyra Biosciences.
Tyra Biosciences share price has been volatile around the latest Dabogratinib update, with a 1-day share price return of 1.03% and 7-day share price return of 4.47%, set against a 30-day share price return that is...